Category: Non Small Cell Lung Cancer (NSCLC)

Lung Cancer Updates from 2017 ASCO Annual Meeting

Each year in early June the American Society for Clinical Oncology holds its Annual Meeting (called simply “ASCO”) in Chicago. The theme for the 2017 meeting was “Making a Difference in Cancer Care WITH YOU.” Over 39,000 cancer researchers, clinicians, patient advocates, and industry representatives from around the world gathered to discuss the latest scientific… Read More

Posted by Janet Freeman-Daily on July 26th, 2017

FDA Approves KEYTRUDA as First-Line Combination Therapy, Irrespective of PD-L1 Expression

Congratulations, Merck, for the approval of KEYTRUDA® in first-line combo therapy irrespective of PD-1 expression. The improved responses seen with KEYTRUDA® plus pemetrexed/carboplatin regimen are significant, and highlight the importance of finding new approaches that address the unmet needs of patients with metastatic nonsquamous non-small cell lung cancer. Read the full press release here

Posted by ALCF Staff on May 10th, 2017

New Clinical Trial for Non-squamous Non-small Cell Lung Cancer

A new study led by researchers at the Indiana University Melvin and Bren Simon Cancer Center may help answer questions about the role of immunotherapy in combination with chemotherapy in treating lung cancer patients whose disease worsened after initial response to immunotherapy. The randomized phase II study, known as HCRN LUN15-233, involves Taxotere® with or… Read More

Posted by ALCF Staff on March 28th, 2017

Do you know a ROS1-fusion positive cancer patient?

In May, 2016, the Bonnie J. Addario Lung Cancer Foundation launched the Global ROS1 Initiative, in partnership with cancer patients whose tumors are driven by ROS1 gene fusions. These ROS1 gene fusions are abnormal changes in cells that drive the growth and spread of several different cancer types such as non-small cell lung, gastric, ovarian,… Read More

Posted by Dr. Guneet Walia on February 23rd, 2017

FDA Approves Genentech’s Cancer Immunotherapy TECENTRIQ (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer

Genentech’s PDL1 drug approved in the second line setting for people “with metastatic non-small cell lung cancer (NSCLC) whose disease progressed during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving atezolizumab.”’s-Cancer-Immunotherapy-TECENTRIQ®-Atezolizumab

Posted by ALCF Staff on October 18th, 2016

Study: A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers

This is a phase 1/2 immunotherapy combination clinical research study for patients who have been diagnosed with one of the following conditions: Diffuse Large B-Cell Lymphoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Carcinoma of Genitourinary Tract (e.g., bladder), Triple Negative Breast Cancer, Squamous Cell Carcinoma of Head and Neck, Ovarian Cancer, Endometrial Cancer, and Renal Cell… Read More

Posted by ALCF Staff on October 18th, 2016

Liquid Biopsy Test Approved by the FDA for EGFR+ Lung Cancer

On June 1, 2016 the US Food and Drug Administration (FDA) approved the first ever blood test to aid clinical decision making for targeted therapies for lung cancer. This blood test, a companion diagnostic called Cobas EGFR Mutation Test v2, allows the detection of mutations in the EGFR (Epidermal Growth Factor Receptor) gene, such as… Read More

Posted by Dr. Guneet Walia on September 29th, 2016

Invictan-2 Clinical Trial for Nonsquamous NSCLC

A new clinical trial from Boehringer Ingelheim will be studying the safety and efficacy of a new drug call INVICTAN-2. The drug is similar to the biologic medication Avastin (bevacizumab) which is already approved as a treatment for nonsquamous non-small cell lung cancer. In order to be eligible to participate, you must meet the following… Read More

Posted by ALCF Staff on August 31st, 2016

ALCMI Study Finds New Targetable Genetic Alteration in NSCLC

The Genomics of Young Lung Cancer (GoYLC) study has identified a unique and targetable new genetic alteration that drives a subset of lung cancer, as reported this month in the prestigious scientific journal, Cancer Discovery. This alteration is a gene fusion, an abnormality whereby a gene fuses with another, and together this gene fusion drives… Read More

Posted by ALCF Staff on August 8th, 2016

Lung Cancer Updates from ASCO 2016

Download PDF of this post What is ASCO? ASCO is the American Society of Clinical Oncology that has an annual meeting each year where key research and clinical medicine highlights are presented by cancer researchers & clinicians to the global community. This was the 52nd Annual Meeting of the American Society of Clinical Oncology, held… Read More

Posted by Dr. Guneet Walia on July 20th, 2016